Agenda


Congress Agenda
The 7th Congress of Hematologists of Serbia will feature lectures by leading experts, panel discussions, workshops, and interactive sessions. The program is designed to provide participants with the latest scientific insights, practical experience, and opportunities for professional development.
The program will combine specialized topics with networking and discussion opportunities, facilitating the exchange of knowledge and ideas across various fields of hematology.
7 Reasons Why Participation Matters
• The program will support the development of hematology in Serbia
• Participants will enhance their professional and scientific competencies
• Opportunities for networking among healthcare professionals and industry
• Latest therapies and technologies will be presented
• The program will support young researchers and specialists
• Strengthening partnerships in the healthcare sector
• Participants will gain brand promotion and visibility among leading experts
AGENDA
- Expert Lecture: Unlocking the Clinical and Therapeutic Value of Scemblix – A Comparative Perspective vs. Other TKI Therapies, Integrating Evidence from Clinical Trials and Real-World Experience — Prof. dr Dragana Milojković
- Expert Panel Discussion: Identifying the Ideal Patient for Scemblix Therapy? Translating Evidence into Everyday Clinical Decision-Making
- 1. Dual complement inhibition in PNH therapy: from biological concept to clinical application — Prof. dr Andrija Bogdanović
- 2. From concept to practice: first experiences with danicopan in patients with PNH — Doc. dr Mirjana Mitrović
- 1. Treatment of blast transformation in MPN — Prof. dr Andrija Bogdanović
- 2. The role of PEG-IFN in the modern treatment of MPN — Prof. dr Ivana Urošević
- 3. New treatment targets in polycythemia vera: the role of clonal and inflammatory pathways — Doc. dr Danijela Leković
- 1. Aplastic anemia: a current approach to diagnosis and treatment — Doc. dr Marijana Virijević
- 2. Diagnosis of myelodysplastic syndrome in 2026 — Prof. dr Andrija Bogdanović
- 3. How to treat patients with myelodysplastic syndrome? — Prof. dr Aleksandar Savić
- 1. The role of NGS in the molecular diagnostics of ALL — Dr Marija Denčić Fekete
- 2. Advances in the treatment of ALL patients — Doc. dr Borivoj Sekulić
- 3. The role of immunotherapy in the treatment of ALL patients — Prof. dr Milena Todorović Balint
- 1. “Diagnosis in the fog: a case that defies logic” — Prof. dr Ivanka Perčić
- 2. “Fertility in the shadow of a rare disease” — Dr Isidora Arsenović
- 3. “Traces in the shadow of anemia: a diagnostic enigma” — Prof. dr Marina Dokić
- 4. “Skin changes with an unexpected background” — Dr Nikola Lemajić
- 5. “Hidden in plain sight: navigating the fog of orbital infiltrates” — Dr Mihailo Smiljanić
- 1. Diagnosis and classification of AML — Dr Ljubomir Jaković
- 2. The role of NGS in molecular diagnosis and risk stratification of acute myeloid leukemia — Prof. dr Ana Vidović
- 3. A new therapeutic approach for “fit” AML patients — Prof. dr Nada Suvajdžić Vuković
- 4. Modern treatment of “unfit” AML patients — Doc. dr Marijana Virijević
- 10.00–10.05Introduction and clinical framework: first-line DLBCL challenges in Serbia
- 10.05–10.25Pushing the boundaries in first-line (1L) DLBCL: European recommendations and clinical evidence
- 10.25–10.45Modern management of relapsed and refractory disease (R/R DLBCL) — Prof. Marco Ladetto (Italy)
- 10.45–11.00Interactive discussion and Q&A: choosing the optimal therapeutic path — Prof. dr Marco Ladetto (all participants)
- 1. Beyond the First Generation: A New Era of BTK Inhibition in CLL — Prof. dr Othman Al Sawaf (Germany)
- 2. Reimagining BTK Inhibition in WM: Efficacy, Safety, and Beyond — Prof. dr Jelena Bila
- 3. From Limited Options to New Possibilities: BTK Inhibition in MZL
- 4. Panel discussion and closing
- 1. Pathophysiology of ITP and novel drugs — Prof. dr Nada Suvajdžić
- 2. Thrombosis in ITP — Prof. dr Svetlana Đukić
- 3. New guidelines — Doc. dr Mirjana Mitrović
- 1. Heparin-induced thrombocytopenia — Doc. dr Mirjana Mitrović
- 2. How I diagnose and treat a patient with eosinophilia — Prof. dr Andrija Bogdanović
- 3. Coagulopathy in the critically ill — Ass. dr Jelena Bodrožić
- 1. Differential diagnosis between invasive aspergillosis and invasive zygomycosis — Prim. dr Snežana Jovanović
- 2. Therapeutic approach to invasive aspergillosis and invasive zygomycosis — Prof. dr Ana Vidović
- 1. Challenges in managing inherited bleeding disorders in women — Prof. dr Predrag Miljić
- 2. Diagnostics of von Willebrand disease — Prof. dr Irena Zupan (Ljubljana)
- 3. Advances in the therapy of von Willebrand disease — Prof. dr Miodrag Vučić
- 1. Ponatinib in the treatment of CML: from resistance to an optimal molecular response — Prof. dr Svetlana Đukić
- 2. The place of tafasitamab in treating patients with R/R DLBCL and FL in clinical practice — Prof. dr Olivera Marković
- 1. MDR Gram-negative infections in hematology patients – clinical challenges and therapeutic options — Ass. dr Marija Elez
- 2. New horizons in the treatment of people with hemophilia — Prof. dr Predrag Miljić
- 3. Discussion
- 1. Prothrombin Belgrade – 10 years later — Prof. dr Predrag Miljić
- 2. Lectures on new gene mutations and mechanisms of antithrombin resistance — lecturers from the Institute of Human Genetics and Genetic Engineering, Belgrade (TBD)
- 10.00–10.15A new paradigm of success in hemophilia A treatment: why has quality of life become our primary therapeutic goal? — Prof. dr Predrag Miljić (UKCS)
- 10.15–10.50Panel – National Hematology Forum – real-world perspectives: how the transformation of care is changing daily life for adult patients with hemophilia A — Prof. dr Predrag Miljić (moderator), Prof. dr Ivana Urošević, Prof. dr Predrag Đurđević, Prof. dr Miodrag Vučić
- 10.50–11.00Q&A and consensus for the future — Prof. dr Predrag Miljić (moderator), Prof. dr Ivana Urošević, Prof. dr Predrag Đurđević, Prof. dr Miodrag Vučić
- 1. MGUS or MGCS – modern diagnostics and therapeutic approach — Asist. dr Aleksandra Sretenović
- 2. Is amyloidosis one disease or many? — Prof. dr Irena Ćojbašić
- 3. Plasma cell leukemia — Doc. dr Danijela Jovanović
- 4. Waldenström macroglobulinemia — Asist. dr Nada Vlaisavljević
- 5. Multiple myeloma: prevention and management of adverse effects of novel immunotherapies — Prof. dr Jelena Bila
- 6. Panel discussion
- 1. In vitro investigation of cytokine effects on hematopoietic cell lines — Prof. dr Vladimir Jurišić
- 2. Bone marrow adipose tissue: its role in the regulation of hematopoiesis and in hematologic malignancies — Drenka Trivanović, Mirjana Čučaković, Marko Vujačić, Marijana Kovačić, Aleksandra Jauković
- 3. Immunomodulatory properties of Galectin-1 and its applicability as a biomarker in hematology — Prof. dr Goran Marjanović
- 4. Analysis of relative BIRC3 gene expression in patients with chronic lymphocytic leukemia — Stanislava Nikolić, Iva Barjaktarović, Maša Sladojević, Tanja Šašić Ostojić, Borivoj Sekulić, Ivanka Perčić, Danijela Agić
- 1. Detection of the leukemic immunophenotype and minimal residual disease in patients with acute leukemias — N. Kraguljac et al.
- 2. The place of progenitor cultures in the modern classification of myeloproliferative neoplasms — D. Šefer et al.
- 3. Detection of FLT3 gene mutations (ITD and TKD) and their assessment in patients with AML — V. Đorđević et al.
- 4. The complexity of diagnosing immune-mediated bone marrow damage through the model of pure red cell aplasia (PRCA) — Bogdanović et al.
- 5. Next-generation sequencing (NGS) in the diagnosis and prognosis of patients with hematologic neoplasms — M. Denčić Fekete et al.
- Round table: where does hematologic diagnostics in Serbia stand – experiences from all centers — lecturers, moderators, all participants
- 1. “Clinically significant interactions among newer drugs in hematology” — Dr sci. med. Dijana Šefer
- 2. “Practical and research aspects of identifying and analyzing drug interactions in hematology” — Prof. dr Dejana Ružić Zečević, Mr ph. Vladimir Vučetić
- 3. “Safe therapy in hematopoietic stem cell transplantation: managing drug interactions in practice” — Asist. dr Marija Elez
- 4. Discussion